Contraception in adolescents with mental disorders: adherence and satisfaction in the use of depot medroxyprogesterone acetate
- PMID: 40242009
- PMCID: PMC12002721
- DOI: 10.61622/rbgo/2025rbgo9
Contraception in adolescents with mental disorders: adherence and satisfaction in the use of depot medroxyprogesterone acetate
Abstract
Objective: To evaluate the continuation rate, satisfaction, and reasons for discontinuation of depot medroxyprogesterone acetate (DMPA) in adolescents treated in a mental health service.
Methods: Prospective cohort study conducted in a reference unit for the care of adolescents with mental disorders (MDs) and intellectual disabilities (IDs). All patients received a gynecological consultation and an educational group on contraceptive methods. Sociodemographic data on age, education and gynecological data (menarche, coitarche, regularity of menstrual cycles and presence of symptoms) were collected. Follow-up was quarterly for 12 months, during which symptoms, desire to continue, and satisfaction with the use of the quarterly injectable were assessed.
Results: Eight hundred and sixty-two sexually active adolescents were supported, 532 adolescents chose to use the quarterly injectable, and 69 of these agreed to participate in the study. The mean age of users was 15.5 years (SD=0.91). After 12 months of follow-up, 34 (49.3%) of the 69 adolescents continued to use the method and 36 (52.3%) were satisfied. Among the 33 (47.8%) who discontinued use, the most common reasons were irregular bleeding and weight gain.
Conclusions: Adolescents with intellectual disabilities and/or other mental disorders showed a significant rate of continuation and satisfaction with the use of the depot medroxyprogesterone acetate at 12 months, and the most common reasons for discontinuation were irregular uterine bleeding and weight gain.
Keywords: Contraception; Medroxyprogesterone acetate; Mental disorders; Pregnancy; Pregnancy in adolescence.
Conflict of interest statement
Conflicts to interest: none to declare.
Figures
Similar articles
-
Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception.Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD005214. doi: 10.1002/14651858.CD005214.pub2. Cochrane Database Syst Rev. 2006. PMID: 16856087 Free PMC article.
-
Effectiveness of levonorgestrel implant and depot medroxyprogesterone acetate injectable for women with HIV on efavirenz.AIDS. 2025 Jul 15;39(9):1197-1203. doi: 10.1097/QAD.0000000000004201. Epub 2025 Apr 2. AIDS. 2025. PMID: 40176530
-
The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.Contraception. 2016 Sep;94(3):202-15. doi: 10.1016/j.contraception.2016.02.003. Epub 2016 Feb 10. Contraception. 2016. PMID: 26874275
-
Progestin-only contraceptives: effects on weight.Cochrane Database Syst Rev. 2016 Aug 28;2016(8):CD008815. doi: 10.1002/14651858.CD008815.pub4. Cochrane Database Syst Rev. 2016. PMID: 27567593 Free PMC article.
-
Immediate start of hormonal contraceptives for contraception.Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD006260. doi: 10.1002/14651858.CD006260.pub3. Cochrane Database Syst Rev. 2012. PMID: 23235628 Free PMC article.
References
-
- Schonewille NN, van den Eijnden MJ, Jonkman NH, van Kempen AA, van Pampus MG, Goedhart FG, et al. Experiences with family planning amongst persons with mental health problems: a nationwide patient survey. Int J Environ Res Public Health. 2023;20(4):3070–3070. doi: 10.3390/ijerph20043070. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous